TNF and Splenomegaly: Importantly, Infliximab administration to chronically infected C57BL/6 mice significantly reduced T. cruzi-induced splenomegaly, a cue previously associated with T. cruzi-induced T- and B-cell polyclonal activation [28]; therefore, anti-TNF therapy interfered with an immunological hallmark of T. cruzi infection.